FacebookXLinkedInInstagram

Esketamine nasal spray prevails in phase 3 trials

By |2018-06-06T07:29:40-07:00June 6th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

MIAMI — The combination of an esketamine nasal spray and an oral antidepressant may provide additional benefits for patients with treatment-resistant major depressive disorder, new research suggested. Two posters at a meeting of the American Society of Clinical Psychopharmacology, formerly known as the New Clinical Drug Evaluation Unit meeting, presented [...]

Read More
 0

AFSP: Can Ketamine Rapidly Reduce Suicidal Ideation?

By |2021-11-11T17:07:05-08:00June 22nd, 2017|Brief Bulletins from the Field, We Know Psychiatry|

This work was sponsored by a Young Investigator Grant from the American Foundation for Suicide Prevention (AFSP) BACKGROUND Suicide is preventable, yet still remains a worldwide cause of death in part due to a lack of available medical interventions that can work during a suicidal crisis. Most potentially helpful medications [...]

Read More
 0

Title

Go to Top